logo

For the Inventor, By the Inventor

Osaka, Japan

Osamu Sakurai

This inventor holds 8 USPTO granted patents and 2 EPO patents. Top assignee: Mitsubishi Tanabe Pharma Corporation. Active years: 2013-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Osamu Sakurai. Retrieved from https://idiyas.com/inventor/osamu-sakurai-g7eau32l

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8

% Patents Active = 62.5


Average Co-Inventor Count = 6.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal8 out of 263 
 
Mitsubishi Tanabe Pharma Corporation
 patents

Years Active: 2013-2019

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 10308636 - Aromatic heterocyclic compound (2019-06-04),
2. 9975871 - Continuous arycyclic compound (2018-05-22),
3. 9546155 - Aromatic heterocyclic compound (2017-01-17),
4. 9302996 - Continuous arycyclic compound (2016-04-05),
5. 8778628 - Arylalkylamine compound and process for preparing the same (2014-07-15),
6. 8759387 - Arylalkylamine compound and process for preparing the same (2014-06-24),
7. 8703721 - Arylalkylamine compound and process for preparing the same (2014-04-22),
8. 8362274 - Arylalkylamine compound and process for preparing the same (2013-01-29),

Title: The Innovations of Osamu Sakurai

Introduction

Osamu Sakurai is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing compounds that address critical health issues such as obesity and diabetes.

Latest Patents

Sakurai's latest patents include an aromatic heterocyclic compound, which is represented by a specific general formula. This compound is useful as a prevention and treatment agent for obesity, diabetes, and related conditions. Another notable patent is for a continuous arycyclic compound, which exhibits DGAT1 inhibitory activity. This compound is beneficial for the prophylaxis and treatment of obesity, hyperlipidemia, and various metabolic disorders.

Career Highlights

Osamu Sakurai is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to innovate in the pharmaceutical sector. His research and development efforts have led to advancements in treatments that can significantly improve patient outcomes.

Collaborations

Sakurai has collaborated with notable colleagues, including Kunio Saruta and Norimitsu Hayashi. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Osamu Sakurai's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to addressing significant health challenges. His work continues to pave the way for new treatments that can improve the quality of life for many individuals.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…